The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would funnel crucial ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Novavax Inc (NVAX) reports a 65% revenue increase and secures major partnerships, despite facing regulatory uncertainties and strategic challenges.

Jan 20 (Reuters) - Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with Pfizer ‌to develop vaccine products ⁠for infectious diseases. I stopped shopping for a year and saved $6 ...

・Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...

GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of the agreement, Pfizer will ...